| 1 |
Kwong AJ, Kim WR, Lake JR, et al. OPTN/SRTR 2022 annual data report: liver[J]. Am J Transplant, 2024, 24(2S1): S176- S265.
|
| 2 |
窦科峰，张玄，杨志鹏. 中国肝移植的发展与挑战[J]. 中华外科杂志，2024, 62(1): 1-5.
|
| 3 |
Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2 000 cases[J]. Clin Transplant, 2018, 32(6): e13259.
|
| 4 |
Subramanian AK, Theodoropoulos NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation[J]. Clin Transplant, 2019, 33(9): e13513.
|
| 5 |
Rashid HU, Begum NAS, Kashem TS. Mycobacterial infections in solid organ transplant recipients[J]. Korean J Transplant, 2021, 35(4): 208-217.
|
| 6 |
Chung H, Kim SH, Jo KW, et al. Clinical characteristics and risk factors of early-onset tuberculosis after liver transplantation[J]. Transplant Proc, 2021, 53(5): 1694-1699.
|
| 7 |
Nguyen Van R, Houssel-Debry P, Erard D, et al. Characteristics, management, and outcome of tuberculosis after liver transplant: a case series and literature review[J]. Infect Dis Now, 2024, 54(3): 104869.
|
| 8 |
Subramanian AK, Morris MI; AST Infectious Diseases Community of Practice. Mycobacterium tuberculosis infections in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 68-76.
|
| 9 |
Chandra P, Grigsby SJ, Philips JA. Immune evasion and provocation by Mycobacterium tuberculosis[J]. Nat Rev Microbiol, 2022, 20(12): 750-766.
|
| 10 |
Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review[J]. J Gastroenterol Hepatol, 2008, 23(2)：192-202.
|
| 11 |
Trofe-Clark J, Lemonovich TL; AST Infectious Diseases Community of Practice. Interactions between anti-infective agents and immunosuppressants in solid organ transplantation[J]. Am J Transplant, 2013, 13(Suppl 4): 318-326.
|
| 12 |
石炳毅，王强，于涛. 器官移植术后结核病临床诊疗技术规范(2019版)[J]. 器官移植，2019, 10(4): 359-363.
|
| 13 |
赵东，唐建信，杨根东，等. 肝移植术后肺部结核分枝杆菌感染的临床诊治分析[J/CD]. 实用器官移植电子杂志，2023, 11(1): 19-22.
|
| 14 |
Abad CLR, Razonable RR. Donor derived Mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review[J]. Transpl Infect Dis, 2018, 20(5): e12971.
|
| 15 |
Drain PK, Bajema KL, Dowdy D, et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection [J]. Clin Microbiol Rev, 2018, 31(4) ：e00021-18.
|
| 16 |
Lee YW, Chung H, Kim SH, et al. Safety and outcome of treatment of latent tuberculosis infection in liver transplant recipients[J]. Infection, 2024, 52(3): 1055-1061.
|
| 17 |
许瀛，臧运金，林栋栋. 肝移植合并结核感染的诊疗进展[J]. 肝胆胰外科杂志，2017, 29(3): 260-264.
|
| 18 |
Malinis M, Koff A. Mycobacterium tuberculosis in solid organ transplant donors and recipients [J]. Curr Opin Organ Transplant, 2021, 26(4): 432-439.
|
| 19 |
Kim SH, Oh S, Nham E, et al. Risk groups of developing active tuberculosis in liver transplant recipients in a tuberculosis endemic area: risk stratification by chest image and interferon gamma release assay[J]. Int J Infect Dis, 2021, 113: 359-366.
|